SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Citibank, N.A./ADR – ‘F-6 POS’ on 4/26/24 re: Burning Rock Biotech Ltd.

On:  Friday, 4/26/24, at 8:30am ET   ·   Accession #:  1193805-24-563   ·   File #:  333-238921

Previous ‘F-6 POS’:  ‘F-6 POS’ on 4/1/24   ·   Latest ‘F-6 POS’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/24  Citibank, N.A./ADR                F-6 POS                2:247K Burning Rock Biotech Ltd.         E-Data Systems, Inc./FA

Post-Effective Amendment of an ‘F-6EF’ Registration   —   Form F-6

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: F-6 POS     Post-Effective Amendment of an 'F-6EF'              HTML     56K 
                Registration                                                     
 2: EX-99.(A)(I)  Miscellaneous Exhibit                             HTML    190K 


‘F-6 POS’   —   Post-Effective Amendment of an ‘F-6EF’ Registration


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

As filed with the Securities and Exchange Commission on April 26, 2024

Registration No. 333- 238921

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

AMERICAN DEPOSITARY RECEIPTS

 

 

 

Burning Rock Biotech Limited

(Exact name of issuer of deposited securities as specified in its charter)

 

 

 

N/A

(Translation of issuer’s name into English)

 

 

 

The Cayman Islands

(Jurisdiction of incorporation or organization of issuer)

 

 

 

CITIBANK, N.A.

(Exact name of depositary as specified in its charter)

 

 

 

388 Greenwich Street

New York, New York 10013

(877) 248-4237

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

 

 

 

Cogency Global Inc.

122 East 42nd Street, 18th Floor

New York, NY 10168

+1-800-221-0102 (Address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

 

Shuang Zhao

Cleary Gottlieb Steen & Hamilton LLP

c/o 37th Floor, Hysan Place

500 Hennessy Road, Causeway Bay

Hong Kong

+852 2532 3783

 

Herman H. Raspé, Esq.

Patterson Belknap Webb & Tyler LLP

1133 Avenue of the Americas

New York, New York 10036

(212) 336-2301

  

 

 

It is proposed that this filing become effective under Rule 466: immediately upon filing.
     
 

on date and time.

 

If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

 

 

 

The Registrant hereby amends this Post-Effective Amendment No. 2 to Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Post-Effective Amendment No. 2 to Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Post-Effective Amendment No. 2 to Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

  

 

 

 

 

This Post-Effective Amendment No. 2 to Registration Statement on Form F-6 may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

 

 

 

 

 

PART I

 

INFORMATION REQUIRED IN PROSPECTUS

 

Cross Reference Sheet

 

Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

 

Item Number and Caption

 

Location in Form of American

Depositary Receipt (“Receipt”)
Filed Herewith as Prospectus

     
1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
       
2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
         
Terms of Deposit:    
     
  (i) The amount of deposited securities represented by one American Depositary Share (“ADSs”)   Face of Receipt  - Upper right corner.
         
  (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17) and (18).
         
  (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
         
  (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
Reverse of Receipt - Paragraph (18).
         
  (v) The sale or exercise of rights  

Reverse of Receipt – Paragraphs (15) and (17).

         
  (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

Face of Receipt - Paragraphs (3) and (6); 

Reverse of Receipt - Paragraphs (15) and (17).

         
  (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
         
  (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
         
  (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10).

  

I-1

 

 

 

Item Number and Caption 

 

Location in Form of American

Depositary Receipt (“Receipt”)
Filed Herewith as Prospectus

         
  (x) Limitation upon the liability of the Depositary  

Face of Receipt - Paragraph (8);

Reverse of Receipt - Paragraphs (20) and (21).

         
  (xi) Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
         
Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

 

The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, is required to file or submit certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

                  

I-2

 

 

 

PROSPECTUS

 

The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amendment No. 1 to Deposit Agreement filed as Exhibit (a)(i) to this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 and is incorporated herein by reference.

 

 

I-3

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 3.EXHIBITS

 

(a)(i)Form of Amendment No. 1 to Deposit Agreement, by and among Burning Rock Biotech Limited (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(i).

 

(a)(ii)Deposit Agreement, dated as of June 16, 2020, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ___ Previously filed as Exhibit (a)(ii) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. No.: 333-238921) with the Commission on October 31, 2022.

 

(b)London Stock Exchange Listing Letter Agreement, dated as of October 28, 2022, by and between the Company and the Depositary. ___ Previously filed as Exhibit (b) to the Post-Effective Amendment No. 1 to Form F-6 Registration Statement (Reg. No.: 333-238921) with the Commission on October 31, 2022.

 

(c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

 

(d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ None.

 

(e)Certificate under Rule 466. ___ None.

 

(f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

  

II-1

 

 

Item 4.UNDERTAKINGS

 

(a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

 

(b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

 

 

II-2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among Burning Rock Biotech Limited, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 26th day of April 2024.

  

 

Legal entity created by the Deposit Agreement, under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing Class A ordinary shares of Burning Rock Biotech Limited.

 

CITIBANK, N.A., solely in its capacity as Depositary

     
  By: /s/ Joseph Connor
  Name: Joseph Connor

Title: Attorney-in-Fact

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Burning Rock Biotech Limited certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Shanghai, China, on April 17, 2024.

  

 

BURNING ROCK BIOTECH LIMITED

     
  By: /s/ Yusheng Han
  Name: Yusheng Han

Title: Chairman of the Board of Directors and

          Chief Executive Officer

 

 

 

 

 

POWERS OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Yusheng Han and Leo Li, and each of them, his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement and any and all related registration statements pursuant to Rule 462(b) of the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Under the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities indicated on April 26, 2024.

 

Signature

 

  Title
/s/ Yusheng Han   Chairman of the Board of Directors and Chief Executive Officer (Principal Executive Officer)
Name: Yusheng Han    
     
/s/ Zhihong (Joe) Zhang   Director and Chief Technology Officer
Name: Zhihong (Joe) Zhang    
    Director and Chief Financial Officer (Principal Financial
/s/ Leo Li   Officer And Principal Accounting Officer)
Name: Leo Li    
     
/s/ Gang Lu   Director
Name: Gang Lu    
     
/s/ Feng Deng   Director
Name: Feng Deng    
     
/s/ Wendy Hayes   Director
Name: Wendy Hayes    
     
/s/ Min-Jui Richard Shen   Director
Name: Min-Jui Richard Shen    
     
/s/ Licen Lisa Xu   Director
Name: Licen Lisa Xu    
     

 

 

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Burning Rock Biotech Limited has signed this Post-Effective Amendment No. 2 to Registration Statement on Form F-6 in New York, New York on April 26, 2024.

 

 

Authorized U.S. Representative

 

Cogency Global Inc.

 
     
By: /s/ Colleen A. De Vries  
Name: Colleen A. De Vries

Title: Senior Vice President on behalf of Cogency Global Inc.

 
 

 

 

 

 

Index to Exhibits

 

Exhibit Document

Sequentially

Numbered Page

     
(a)(i) Form of Amendment No. 1 to Deposit Agreement  

 

 

 

 

 

 

 

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘F-6 POS’ Filing    Date    Other Filings
Filed on:4/26/246-K
4/17/24
10/31/22F-6 POS
10/28/22
6/16/20UPLOAD
 List all Filings 
Top
Filing Submission 0001193805-24-000563   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 11:47:42.1am ET